Delaware is the US’s go-to venue for pharma patent litigation, but there could be trouble ahead 11 May 18
A burgeoning caseload and the retirement of key specialist judges might adversely affect the performance of the US district court for the District of Delaware in pharma patent litigation, according to Owen Byrd, general counsel and chief evangelist of Lex Machina, which has just produced its 2018 Hatch-Waxman ANDA Litigation Report.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
Well-written, in-depth coverage that is not found on this side of the ‘pond’. Thank you for that.
Frederic M Wilf
Technology, intellectual property and business lawyer
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email